25th September 2025 | 11:00 AM SGT
The rapid evolution of biologics manufacturing is driving the need for highly adaptable, contamination-controlled, and economically viable production platforms. Single-use bioprocessing technologies (SUS) have emerged from niche applications to mainstream adoption, enabling streamlined facility design, enhanced production agility, and sustainable operations.
This webinar provides a deep technical dive into the latest advancements in SUS, covering next-generation polymer chemistries, closed-system process designs, automation-enabled monitoring, and hybrid facility architectures that combine stainless steel and disposable components.
Through real-world case studies and data-driven insights, participants will explore operational, economic, and regulatory aspects of SUS integration in monoclonal antibody production, and gain strategies for future-ready, flexible biologics manufacturing.
Technical Director, Duoning Biotech
Dr Ramesh Mundlamuri has over 19 years of experience in various biopharmaceutical organizations and has ample experience in various divisions and sections of the biopharmaceutical industry, including Research & Development, Technology Transfer, Commercial Manufacturing, Product & Process Development, Operations Management and so on.
Prior to joining Duoning, he worked at Biological E in Hyderabad, India. In his role as Assistant General Manager, he led the commercial manufacturing of polysaccharide conjugate and protein-based Vaccines. Before that, he worked for Panacea Biotech, Sartorius, Sanofi and Krebs Biochemical Industries.
Dr Ramesh Mundlamuri is well-versed in cGMP, GLP, GDP and various regulatory bodies (WHO, EU, ROW, FDA, NRA). He also possesses extensive experience in the management of several vaccines, including polysaccharide vaccines, recombinant viral proteins, conventional vaccines and carrier protein.